Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide

Background: Current treatments for hypercalcemia caused by lung cell carcinomas producing parathyroid hormone-related peptide (PTH-rp) have limited efficacy, probably because of their lack of effect on PTH-rp secretion. In this case study we explored the efficacy of the calcimimetic cinacalcet as su...

Full description

Bibliographic Details
Main Authors: Anneke Bech, Koen Smolders, Darryl Telting, Hans de Boer
Format: Article
Language:English
Published: Karger Publishers 2012-01-01
Series:Case Reports in Oncology
Subjects:
Online Access:http://www.karger.com/Article/FullText/335676
id doaj-53aa7f83b4b34469a6e2afa33fe19d2c
record_format Article
spelling doaj-53aa7f83b4b34469a6e2afa33fe19d2c2020-11-24T22:37:25ZengKarger PublishersCase Reports in Oncology1662-65752012-01-01511810.1159/000335676335676Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related PeptideAnneke BechKoen SmoldersDarryl TeltingHans de BoerBackground: Current treatments for hypercalcemia caused by lung cell carcinomas producing parathyroid hormone-related peptide (PTH-rp) have limited efficacy, probably because of their lack of effect on PTH-rp secretion. In this case study we explored the efficacy of the calcimimetic cinacalcet as suppressor of PTH-rp production. Patient: A 57-year-old male with severe and recurrent hypercalcemia induced by a PTH-rp-producing squamous cell lung carcinoma, stage cT4N3M1b, poorly responding to standard treatments. Results: Serum PTH-rp levels were not affected by saline, calcitonin or zoledronate. PTH-rp decreased during chemotherapy and cinacalcet monotherapy. The combination of chemotherapy plus cinacalcet was most effective in rapidly reducing serum calcium and PTH-rp. Conclusion: This case study is the first to suggest that cinacalcet may be of value in some cases of PTH-rp-dependent hypercalcemia. Corroborative evidence is needed.http://www.karger.com/Article/FullText/335676HypercalcemiaParathyroid hormone-related peptideLung cell carcinomaCinacalcet
collection DOAJ
language English
format Article
sources DOAJ
author Anneke Bech
Koen Smolders
Darryl Telting
Hans de Boer
spellingShingle Anneke Bech
Koen Smolders
Darryl Telting
Hans de Boer
Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide
Case Reports in Oncology
Hypercalcemia
Parathyroid hormone-related peptide
Lung cell carcinoma
Cinacalcet
author_facet Anneke Bech
Koen Smolders
Darryl Telting
Hans de Boer
author_sort Anneke Bech
title Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide
title_short Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide
title_full Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide
title_fullStr Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide
title_full_unstemmed Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide
title_sort cinacalcet for hypercalcemia caused by pulmonary squamous cell carcinoma producing parathyroid hormone-related peptide
publisher Karger Publishers
series Case Reports in Oncology
issn 1662-6575
publishDate 2012-01-01
description Background: Current treatments for hypercalcemia caused by lung cell carcinomas producing parathyroid hormone-related peptide (PTH-rp) have limited efficacy, probably because of their lack of effect on PTH-rp secretion. In this case study we explored the efficacy of the calcimimetic cinacalcet as suppressor of PTH-rp production. Patient: A 57-year-old male with severe and recurrent hypercalcemia induced by a PTH-rp-producing squamous cell lung carcinoma, stage cT4N3M1b, poorly responding to standard treatments. Results: Serum PTH-rp levels were not affected by saline, calcitonin or zoledronate. PTH-rp decreased during chemotherapy and cinacalcet monotherapy. The combination of chemotherapy plus cinacalcet was most effective in rapidly reducing serum calcium and PTH-rp. Conclusion: This case study is the first to suggest that cinacalcet may be of value in some cases of PTH-rp-dependent hypercalcemia. Corroborative evidence is needed.
topic Hypercalcemia
Parathyroid hormone-related peptide
Lung cell carcinoma
Cinacalcet
url http://www.karger.com/Article/FullText/335676
work_keys_str_mv AT annekebech cinacalcetforhypercalcemiacausedbypulmonarysquamouscellcarcinomaproducingparathyroidhormonerelatedpeptide
AT koensmolders cinacalcetforhypercalcemiacausedbypulmonarysquamouscellcarcinomaproducingparathyroidhormonerelatedpeptide
AT darryltelting cinacalcetforhypercalcemiacausedbypulmonarysquamouscellcarcinomaproducingparathyroidhormonerelatedpeptide
AT hansdeboer cinacalcetforhypercalcemiacausedbypulmonarysquamouscellcarcinomaproducingparathyroidhormonerelatedpeptide
_version_ 1725717124399235072